Clinical Trial: HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study

U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07874308) titled 'HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study' on Sept. 24.

Brief Summary: HR20013 is a newly approved medicine in China to prevent nausea and vomiting from anticancer treatment. This prospective, observational, multicenter real-world study will enroll about 3,000 patients receiving this medicine as routine care at over 30 hospitals in China, including 100 with mild to moderate hepatic impairment. Following usual clinical practice, it will evaluate how well the medicine prevents nausea and vomiting and its safety to guide clinical use.

Study Start Date: July 15

Study Type: OBSERVATIO...